Plato Investment Management Ltd Buys Shares of 5,423 Illumina, Inc. $ILMN

Plato Investment Management Ltd purchased a new position in shares of Illumina, Inc. (NASDAQ:ILMN) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 5,423 shares of the life sciences company’s stock, valued at approximately $948,000.

Several other hedge funds have also recently modified their holdings of ILMN. HighPoint Advisor Group LLC increased its stake in Illumina by 3.7% in the 4th quarter. HighPoint Advisor Group LLC now owns 2,218 shares of the life sciences company’s stock valued at $291,000 after buying an additional 80 shares during the period. Elevation Wealth Partners LLC raised its position in Illumina by 52.5% during the 2nd quarter. Elevation Wealth Partners LLC now owns 244 shares of the life sciences company’s stock worth $43,000 after buying an additional 84 shares during the last quarter. Meeder Advisory Services Inc. lifted its stake in shares of Illumina by 3.1% in the 1st quarter. Meeder Advisory Services Inc. now owns 2,822 shares of the life sciences company’s stock worth $348,000 after acquiring an additional 85 shares during the period. Toronto Dominion Bank lifted its stake in shares of Illumina by 0.3% in the 4th quarter. Toronto Dominion Bank now owns 33,605 shares of the life sciences company’s stock worth $4,407,000 after acquiring an additional 92 shares during the period. Finally, Panagora Asset Management Inc. boosted its holdings in shares of Illumina by 3.9% in the fourth quarter. Panagora Asset Management Inc. now owns 2,536 shares of the life sciences company’s stock valued at $333,000 after acquiring an additional 96 shares in the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Illumina Stock Performance

Shares of ILMN opened at $188.29 on Wednesday. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53. Illumina, Inc. has a 52-week low of $88.00 and a 52-week high of $207.00. The company has a 50-day simple moving average of $185.05 and a 200-day simple moving average of $151.10. The company has a market capitalization of $28.43 billion, a PE ratio of 35.13, a P/E/G ratio of 2.69 and a beta of 1.44.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The company had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. During the same period in the prior year, the business posted $1.19 earnings per share. The firm’s revenue for the quarter was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Equities research analysts predict that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on ILMN shares. Guggenheim boosted their price target on shares of Illumina from $200.00 to $226.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Canaccord Genuity Group raised their price objective on shares of Illumina from $190.00 to $205.00 and gave the company a “hold” rating in a research report on Monday, August 3rd. TD Cowen lifted their price objective on Illumina from $192.00 to $210.00 and gave the company a “hold” rating in a report on Friday, July 31st. Citigroup boosted their target price on Illumina from $95.00 to $113.00 and gave the stock a “sell” rating in a research report on Monday, August 3rd. Finally, Zacks Research raised Illumina from a “hold” rating to a “strong-buy” rating in a research note on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $188.40.

Insider Transactions at Illumina

In other Illumina news, SVP Patricia Leckman sold 783 shares of the business’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $162.59, for a total transaction of $127,307.97. Following the sale, the senior vice president directly owned 21,259 shares in the company, valued at approximately $3,456,500.81. The trade was a 3.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 457,858 shares of the company’s stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $200.10, for a total value of $91,617,385.80. Following the completion of the sale, the director directly owned 2,372,694 shares in the company, valued at $474,776,069.40. This trade represents a 16.18% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 1,415,351 shares of company stock valued at $255,966,311. Company insiders own 2.90% of the company’s stock.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.